Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo

BACKGROUND: GEN-003 is an investigational genital herpes immunotherapy comprising gD2ΔTMR, an HSV-2 antigen that induces neutralizing antibody and T cell responses, ICP4.2, an HSV-2 T cell antigen selected through human T cell screens, and Matrix-M2™, a saponin-based adjuvant. This Phase 2b study wa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Heineman, Thomas C, Bernstein, David, Wald, Anna, Van Wagoner, Nicholas, Leone, Peter, Mayer, Kenneth, Lucksinger, Gregg, Win, Sandra, Koltun, William, Desai, Nisha, Oliphant, Thomas, Natenshon, Andrew, McNeil, Lisa K, Flechtner, Jessica B, Hetherington, Seth
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5631773/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx162.140
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados